CD33 and neoplasm: Due to the presence of CD33 in normal myeloid progenitors, CD33-CAR T not only clear out tumor cells, but also wipe out myeloid progenitors, resulting in on-target off-tumor side effects, which explained the failure of CD33-CAR T clinical trials (Gill et al., 2014).